Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Bayer hits 8-month high as investors welcome CEO change

by Staff GBAF Publications Ltd
0 comment

BERLIN (Reuters) -Bayer shares rose as much as 5% in early Thursday trading to an eight month high, adding to gains from the day before when the German drugs to pesticides group named former Roche executive Bill Anderson as its next CEO.

The stock jumped 6% late Wednesday, after the appointment was announced about 15 minutes before the market close.

Some investors cashed in their profits on Thursday morning, however. The stock was up 0.5% to 62.82 euros at 0845 GMT.

Anderson’s appointment as CEO from June came after shareholder pressure for an external successor to Werner Baumann, who engineered Bayer’s troubled Monsanto takeover.

Juergen Molnar, capital markt strategist at brokerage RoboMarkets, said the stock had considerable potential for further gains even after the rally.

The shares are up 30% since the start of the year, helping to offset a more than five year downturn related to the takeover of Monsanto. In June 2018, when the acquisition was completed, the shares traded at around 100 euros.

(Reporting by Miranda Murray, Kirsti Knolle; editing by Rachel More and Mark Potter)